Emoxypine ampoules 1% 1 ml №10

Dosage form

Injection

Composition

1 ml of solution contains: methylethylpyridinol hydrochloride (emoxipin) - 10 mg.
Excipients: hydrochloric acid 0.1 M, water for injection.

Packing

In the ampoule 1 ml of 1% solution for injection. In the cell contour packaging 5 ampoules. In a cardboard bundle 2 packs.

Mechanism of action

Emoxypine is an antioxidant. Emoxypine reduces the permeability of the vascular wall, is an inhibitor of free radical processes, antihypoxant and antioxidant.
Reduces blood viscosity and platelet aggregation, increases the content of cyclic nucleotides (cyclic adenosine monophosphate and cyclic guanosine monophosphate) in platelets and brain tissue, has fibrinolytic activity, reduces the permeability of the vascular wall and the risk of hemorrhage, contributes to their resorption.
Expands coronary vessels, in the acute period of myocardial infarction limits the size of the source of necrosis, improves the contractility of the heart and the function of its conduction system.
With elevated blood pressure has a hypotensive effect. In acute ischemic disorders of cerebral circulation reduces the severity of neurological symptoms, increases the resistance of tissue to hypoxia and ischemia.
Possesses retinoprotective properties, protects the retina from the damaging effects of high-intensity light, promotes the resorption of intraocular hemorrhages, and improves the microcirculation of the eye.

- Subconjunctival and intraocular hemorrhage of various origins.
- Angioretinopathy (including diabetic retinopathy).
- Central and peripheral chorioretinal dystrophy.
- Thrombosis of the central vein of the retina and its branches.
- Complications of myopia.
- Angiosclerotic macular dystrophy (dry form).
- Surgical intervention in the eyes, the state after surgery for glaucoma with choroidal detachment.
- Dystrophic diseases of the cornea.
- Trauma, inflammation and burn of the cornea.
- Protection of the cornea (when wearing contact lenses) and the retina of the eye from exposure to high-intensity light (laser and sunburns, with laser coagulation).

Contraindications

- Increased individual sensitivity to the drug.
- Pregnancy, lactation.
- Children under 18 years old.

Pregnancy and Breastfeeding

Contraindicated use during pregnancy and breastfeeding.

Dosage and administration

The Emoxypine solution is administered subconjunctivally or parabulbally. If necessary, possible retrobulbar injection. Subconjunctivally injected with 0.2-0.5 ml (2-5 mg), parabulbarno - 0.5-1 ml (5-10 mg) of a 1% solution. The drug is used once a day or every other day for 10-30 days.If necessary, treatment can be repeated 2-3 times a year. Retro-bulbar injected with 0.5-1 ml of 1% solution once a day for 10-15 days.
To protect the retina during laser coagulation (including with limiting and destructive coagulation of tumors) - parabulbar or retrobulbar in 0.5-1 ml of 1% solution for 24 hours and 1 hour before coagulation; then - the same doses (0.5 ml of 1% solution) 1 time per day for 2-10 days.

Adverse reactions

Short-term agitation, drowsiness, high blood pressure, allergic reactions (skin rashes, etc.).
Local reactions: pain, burning, itching, hyperemia, compaction of paraorbital tissues (resolves independently).

Treatment should be under the control of blood pressure and blood clotting.

Drug interactions

Pharmaceutical incompatible with other drugs.

To store in the place protected from light, at a temperature not above 25 ° C.